Lg Life Sciences, Limited

Lg Chem, Ltd

Suk Young Choi

Hoon Sung Jeh

Myung Jin Kim

Seung Joo Lee

Jin Eon So

Youn Kyung Ko

Kyu Chan Kwon

Jin-Seok Oh

Ji Eon Kim

Young Cheol Kang

Jin-Seok c/o Lg Life Sciences Ltd Oh

Ji Eon c/o Lg Life Sciences Ltd Kim

The present invention relates to a stable liquid formulation of etanercept (recombinant p75 sTNFR:Fc fusion protein), and more particularly, to a liquid formulation comprising one or more stabilizers selected from the group consisting of methionine, lysine, histidine, and pharmaceutically acceptable salts thereof in an amount sufficient to reduce by-product formation of etanercept during storage. The liquid formulation according to the present invention effectively reduces production of etanercept by-products and to stably maintain its pharmaceutical efficacies for long-term storage. Therefore, the reconstitution procedure is not required before administration, and the sterile formulation can be administered to patients to ensure patient safety. Thus, it can be applied to the fields in need of etanercept treatment.

Stable liquid formulation of etanercept

The present invention provides an aqueous formulation of human erythropoietin having the storage stability over a long period without serum albumin, in which the formulation comprises a pharmaceutically effective amount of human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers; isotonic reagent; and buffering reagent.

Stable, aqueous solution of human erythropoietin, not containing serum albumin

Disclosed is a sustained release composition of a protein drug. The composition comprises a carrier substrate and a protein drug incorporated in the carrier substrate. The carrier substrate is consisting essentially of a hyaluronic acid or its salts, an amino acid, and a polyalkyl oxide.

Sustained release composition of protein drug

Growing community of inventors

Daejeon, South Korea

Suk Young Choi